FDAnews
www.fdanews.com/articles/195586-advisory-committee-turns-down-nektar-therapeutics-abuse-deterrent-opioid
Nektar Therapeutic Logo

Advisory Committee Turns Down Nektar Therapeutics’ Abuse-Deterrent Opioid

January 22, 2020

Two FDA advisory committees unanimously shot down Nektar Therapeutics’ investigational opioid treatment NKTR-181.

NKTR-181 (oxycodegol; mPEG6-oxycodol) is an abuse-deterrent opioid for adults with chronic lower back pain severe enough for long-term opioid treatment and for which alternative treatment options are inadequate.

The Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee found that there was not enough data to recommend FDA approval.

View today's stories